Aquestive Therapeutics Announces FDA Acceptance of Anaphylm™ NDA Resubmission and PDUFA Goal Date of March 16, 2027

Go back to Aquestive Therapeutics Announces FDA Acceptance of Anaphylm™ NDA Resubmission and PDUFA Goal Date of March 16, 2027
(NASDAQ: AQST) Delayed: 4.08 +0.03 (0.74%)
Previous Close $4.05    52 Week High $ 
Open $4.08    52 Week Low $ 
Day High $4.19    P/E N/A 
Day Low $4.02    EPS $ 
Volume 1,571,350